14.06.2011
- Biotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough...
17.05.2010
- Astellas Pharma, Japan's No.2 drugmaker, seeks to buy at least 90% of shares in U.S. drugmaker OSI Pharmaceuticals with its tender offer, the company's chief executive said on...
